Clinical trials: Blepharospasm
Bilateral Blepharospasm (BEB)
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
This phase 3 study will serve to collect efficacy and safety data of two different doses of NT 201 in subjects suffering from Bilateral Blepharospasm (BEB) who are BTX treatment-naïve.
- Trial name
- NCT01896895
- Testing
- IncobulinumtoxinA (Xeomin), 25 Units, IncobotulinumtoxinA (Xeomin), 12.5 Units, IncobotulinumtoxinA (Xeomin), 35 Units
- Where
- 11 sites in Greece, Malaysia and 1 more
- Volunteers
- 61 people
- Sponsor
- Merz Pharmaceuticals GmbH
Blepharospasm
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA…
- Trial name
- NCT00406367
- Testing
- incobotulinumtoxinA (Xeomin)
- Where
- 2 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Merz Pharmaceuticals GmbH
Blepharospasm
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm.
- Trial name
- NCT00761592
- Testing
- Botulinum Toxin Type A 900kDa, Botulinum Toxin Type A 150kDa
- Where
- 3 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Allergan
Cervical Dystonia, Blepharospasm
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical…
- Trial name
- NCT01814774
- Testing
- No Intervention
- Where
- 2 sites in Norway, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Allergan
Blepharospasm, Torticollis
MDs on Botox Utility (MOBILITY)
The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.
- Conditions
- Blepharospasm, Torticollis, Strabismus, Muscle Spasticity
- Trial name
- NCT00535938
- Testing
- botulinum toxin type A
- Where
- Canada
- Volunteers
- 1,372 people
- Sponsor
- Allergan